Finerenone in Type 1 Diabetes and Chronic Kidney Disease
University Medical Center Groningen · University of Groningen · +22 more institutions
Abstract
The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown.
of body-surface area), and albuminuria (urinary albumin-to-creatinine ratio [with albumin measured in milligrams and creatinine measured in grams], 200 to
Citation impact
- FWCI
- 94.50
- Percentile
- 100%
- References
- 22
Authors
19- HJHiddo J.L. HeerspinkCorresponding
University Medical Center Groningen, University of Groningen, UNSW Sydney
- ALAndreas L. Birkenfeld
Deutsches Diabetes-Zentrum e.V., German Center for Diabetes Research, Heinrich Heine University Düsseldorf, University of Tübingen
- DZDavid Z.I. Cherney
University Health Network
- HMHelen M Colhoun
Edinburgh Cancer Research
- PGPer-Henrik Groop
University of Helsinki, Helsinki University Hospital
Topics & keywords
- Kidney disease
- Type 1 diabetes
- Diabetes mellitus
- MEDLINE
- Nephropathy
- Disease
- Hemodialysis
- Good health and well-being